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Abstract
Background: Human papillomavirus is responsible for a variety of diseases including grade 2 and 3 vulvar and
vaginal intraepithelial neoplasia. The aim of this study was to assess parts of the burden of the last diseases
including treatment costs. The direct medical resource use and cost of surgery associated with neoplasia and
related diagnostic procedures (statutory health insurance perspective) were estimated, as were the indirect costs
(productivity losses) associated with surgical treatment and related gynaecology visits for diagnostic purposes.
Methods: Data from 1991-2008 were retrospectively collected from patient records of the outpatient unit of the
Gynaecological Dysplasia Clinic, Heinrich Heine University, Dusseldorf, Germany. Two subgroups of patients were
analysed descriptively: women undergoing one surgical procedure related to a diagnosis of vulvar and/or vaginal
intraepithelial neoplasia, and women undergoing two or more surgical procedures. Target measures were per-
capita medical resource consumption, direct medical cost and indirect cost.
Results: Of the 94 women analysed, 52 underwent one surgical intervention and 42 two or more interventions
(mean of 3.0 interventions during the total period of analysis). Patients undergoing one surgical intervention
accrued €881 in direct costs and €682 in indirect costs; patients undergoing more than one intervention accrued
€2,605 in direct costs and €2,432 in indirect costs.
Conclusions: The economic burden on German statutory health insurance funds and society induced by surgical
interventions and related diagnostic procedures for grade 2/3 vulvar and vaginal neoplasia should not be
underrated. The cost burden is one part of the overall burden attributable to human papillomavirus infections.
Background
Human papillomavirus (HPV) is responsible for a variety
of diseases [1-3]. Discussion concerning HPV and asso-
ciated epidemiology and disease burden, treatment and
vaccination focuses predominantly on cervical cancer
and cervical intraepithelial neoplasia (CIN) as a precur-
sor of cervical cancer in women. While the incidence of
cervical cancer has declined owing to the implementa-
tion of screening programmes, the incidence of vulvar
intraepithelial neoplasia grades 2 and 3 (VIN 2/3) and
vaginal intraepithelial neoplasia grades 2 and 3 (VaIN 2/
3), primarily caused by HPV 16, have risen in recent
decades. Data from the United States demonstrate a
greater than fourfold increase in carcinoma in situ
within a 30-year period [4]. In 2001, Anders et al.
reported a VIN incidence of 7/100,000 women/year [5].
A German study established the presence of HPV in
more than 90% of VIN 2/3 and VaIN 2/3 cases [6]. The
increase in VIN and VaIN caseloads is attributable to a
rising incidence of HPV infections and improved diag-
nostic procedures. The average age of affected women is
between 40 and 50 years [4,7,8]. VIN is normally multi-
focal and present in combination with VaIN, CIN or
anal intraepithelial neoplasia [9,10]. Severe VIN pro-
gresses to vulvar carcinoma in approximately 9% of
untreated cases [11] and between 3.8% and 6.5% of trea-
ted cases [8,11]. Recurrence is common, being observed
in approximately 30% of VIN lesions [12] and affected
women suffer the individual distress caused by diagnos-
tic and therapeutic procedures.
* Correspondence: sschmitter@spmsd.com
† Contributed equally
4Sanofi Pasteur MSD GmbH, Paul-Ehrlich-Straße 1, 69181 Leimen, Germany
Full list of author information is available at the end of the article
Hampl et al. BMC Infectious Diseases 2011, 11:73
http://www.biomedcentral.com/1471-2334/11/73
© 2011 Hampl et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.In Germany, medical care for women with VIN/VaIN
is provided by primary care physicians, gynaecologists
and dermatologists. For verification of diagnosis, further
evaluation and treatment, patients are normally referred
to an outpatient department of a hospital, generally a
gynaecology department.
To assess the burden of these diseases, the costs for
treatment of VIN/VaIN must be calculated because
these are not currently available in Germany. The aim
of the study was to estimate parts of the burden of dis-
ease on statutory health insurances (SHI) and society by:
1. Estimating the direct medical resource use and
cost of surgery targeted to VIN 2/3 or VaIN 2/3 and
related diagnostic procedures from a SHI
perspective,
2. Approximating the indirect cost (productivity
losses) generated by surgical treatment of VIN 2/3
and VaIN 2/3 and related visits to gynaecologists for
diagnostic purposes.
Methods
Data were retrospectively collected from patient records
between 1991 and 2008 at one study site. The outpati-
ent unit of the Dysplasia Clinic, Department of Obste-
trics and Gynaecology at Heinrich Heine University,
Dusseldorf, Germany, is specialised in the diagnosis and
treatment of female lower genital tract diseases.
All patient entries included in the documentation of
laser treatments were pre-screened by hand-searching to
identify patients who had a (suspected) diagnosis of VIN
2/3 or VaIN 2/3 and had undergone surgical interven-
tion. Patient records of eligible patients were checked in
detail to ensure that they fulfilled the following criteria
for the study:
￿ Had undergone at least one of the following surgi-
cal interventions, either as an outpatient or inpatient
(reference intervention): laser excision, laser vapori-
sation, biopsy, inguinal lymphadenectomy, vulvect-
omy, vulvar resection;
￿ Had been subjected to a definite confirmed diagno-
s i so fV I N2 / 3o rV a I N2 / 3( a sd o c u m e n t e di nt h e
medical records of the study site);
￿ Lived in Germany at the time of intervention.
Patients with diseases other than grade 2 or 3 VIN or
VaIN such as cancer or VIN 1, or those with incomplete
documentation of interventions, were excluded from the
study.
The reference intervention (i.e. the last or only surgi-
cal intervention within the observation period) had to
be performed at the study site; prior interventions (inpa-
tient or outpatient setting) could have taken place at the
same site or at any other German hospital. Before and
after surgical intervention, patients attended gynaecology
outpatient departments of hospitals or office-based
gynaecologists for diagnostic purposes (visit for diagnos-
t i cp u r p o s e s ) .D i a g n o s t i cp r o c e d u r e sw e r en o t
standardised.
The following data were extracted from patient
records using a case report form:
￿ Date of birth;
￿ Diagnoses;
￿ For inpatient surgery: date of admission; method of
intervention; diagnostic procedures; length of stay in
hospital [days], amount reimbursed by SHI [€];
￿ For outpatient surgery: date of surgical interven-
tion; method of intervention; diagnostic procedures;
amount reimbursed by SHI [€];
￿ For visits for diagnostic purposes: date; diagnostic
procedures; amount reimbursed by SHI [€].
Two subgroups of patients were generated:
￿ Subgroup I: women who had undergone one sur-
gery related to VIN 2/3 and/or VaIN 2/3 diagnosis
(the most common patient category);
￿ Subgroup II: women subjected to two or more
surgeries (representing more seriously affected
patients).
Two time periods were analysed for each subgroup
(Figure 1):
1. Main analysis period - a one year period before
the reference intervention, reflecting the time hori-
zon most relevant for VIN 2/3 or VaIN 2/3 surgery;
2. Total analysis period - the period from the first
documented contact with a hospital/gynaecologist
due to VIN 2/3 or VaIN 2/3 to the last reported
contact, covering the full time horizon for which
data were found in patient records at the study site.
1 year = main analysis period
reference
SI
1
st SI 1
stVDP
total analysis period
Figure 1 Main analysis period and total analysis period for
Subgroup II (Schematic diagram). Purple cross = visit(s) at
dysplasia outpatient department or office based specialist for
diagnostic purposes (VDP) Purple line = surgical intervention (SI)
Purple brackets = optional VDP/SI In Subgroup I: main analysis
period = total analysis period
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cost.
Economic burden was estimated from two perspec-
tives:
￿ The SHI perspective takes into consideration medi-
cal resource consumption and fees reimbursed by
SHI;
￿ The social perspective refers additionally to pro-
ductivity losses to society caused by treatment-
related sick leave.
Target measures were per-capita medical resource
consumption, direct medical per-capita costs and indir-
ect per-capita costs. Medical resource consumption for
the patients included in the study was measured by
counting:
￿ The number of surgical interventions due to VIN
2/3 and/or VaIN 2/3 in an inpatient setting and an
outpatient setting;
￿ The number of related outpatient visits for diag-
nostic purposes before and after surgical
interventions.
Data relating to medical resource consumption were
obtained from patient records.
Direct medical costs considered analogously were:
￿ Cost of inpatient surgery;
￿ Cost of outpatient surgery;
￿ Cost of visits for diagnostic purposes.
The direct medical costs were calculated using two
approaches:
￿ The first approach was to use “historical” costs,
fees reimbursed by SHI in the year of surgical inter-
vention and visits for diagnostic purposes as
recorded in patient records. This approach resulted
in “historical” medical costs. For medical services
not performed at the study dysplasia centre, or if no
unit cost was available from patient records, the
mean value of the respective cost category from the
study site was taken as the unit cost.
To describe the trend followed by the three categories
of direct medical costs over the time period examined,
the respective mean values per case were normalised
for six time periods: 1991-2002, 2003, 2004, 2005,
2006 and 2007-2008, using the z-score (zij =( X ij - μ)/
s;i=1 ,2 ,3 ;j=1 ,2 , . . . ,6 ;X ij: mean of cost category i
in time period j, μ: mean of all cost numbers; and s:
standard deviation of all cost numbers).
￿ To adjust for varying prices and fees over the time
period, a scenario analysis was performed on the
basis of unit cost in 2007 as found in patient
records: median unit costs (base case), the lowest
(best case) and the highest (worst case).
Productivity losses due to lost work days because of
visits for diagnostic purposes and in association with
surgical interventions were estimated as a proxy for
indirect costs from society’s perspective, based on the
human capital approach. Per-capita costs were estimated
as the mean duration (in days) per patient off work mul-
tiplied by a daily rate for “loss of productivity”.M e a n
days off work per patient were conservatively estimated
to be 0.5 days for surgery in an outpatient setting or
attendance for diagnostic reasons, and the mean days on
a ward for inpatient surgery (as found in the patient
records). An average sick leave of five days after each
surgical intervention was assumed. A daily rate of €90
(2006 value) was used, following the German Hanover
Consensus, 3
rd edition [13].
T h es a m p l es i z ew a sp l a n n e dt ob eb e t w e e n8 0a n d
100 patients, as this number is known to be sufficient
for precise estimations in cost studies.
Due to the study design and according to national leg-
islative requirements a consultation at the ethics com-
mittee was not necessary. The national guideline for
secondary data analysis [14] need to be complied as we
did a retrospective chart review. Two exceptions from
consultation by the ethics commission are mentioned in
this guideline: 1) all data protection measures are ful-
filled and 2) no relation to the primary data is planned.
Exception 1 was fulfilled because according to the Ger-
man data protection law, data from hospitalized cases
may be used for scientific analyses by the hospital with-
out special patient informed consent by the patients.
Further to that, all patients in the study site signed a
special form that their data may be used for scientific
reasons. No relation to individual data was possible
because all analyses of the primary data were performed
at the study site and left the centre only in an aggre-
gated manner. Therefore the second criterion was ful-
filled, too.
SPSS version 13 G and MS Excel 2007 were used to
perform the analyses. P-values presented here are based
on the Welch test.
Results
A total of 141 patients were eligible for the study; of
these, 94 women fulfilled the inclusion criteria. Reasons
for patient exclusion were no definite confirmation of
VIN or VaIN diagnosis (20 cases), vulvar cancer (11
cases), no patient records (six cases), VIN 1 (four cases),
condylomata (two cases), surgery not linked to VIN/
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lichen sclerosis (one case).
The first documented surgical intervention was in Jan-
uary 1991 and the last was dated February 2008. Diag-
nostic visits were documented from March 1993 to
February 2008.
Of the 94 women included in the analyses, 52 (55%)
underwent one surgical intervention related to VIN 2/3
or VaIN 2/3 diagnosis and were assigned to subgroup I.
42 women (45%) underwent two or more interventions
and were assigned to subgroup II.
Demographics and basic characteristics
Patients in subgroup I had a mean total observation per-
iod of 0.53 years (range 0.01 - 3.64 years; median 0.13
years). The respective figures for subgroup II were 4.35
years (0.11 - 15.42 years; 3.38 years).
The baseline information is presented in table 1. VIN
3 was the dominant diagnosis in each subgroup. The
range of patient ages had a normal distribution in each
group and for both observation periods. Patients sub-
jected to multiple surgical interventions (subgroup II)
were younger on average than the patients who
underwent one surgical intervention (subgroup I) (44 vs.
49 years; p = 0.026).
In subgroup I each of the 52 surgical interventions
was performed at the study site. For women who under-
went surgery more than once (subgroup II), 15 interven-
tions out of 73 (20.5%) in the main analysis period and
33 out of 126 (26.2%) in the total analysis period were
performed at a site other than the study site.
Surgical interventions were predominantly carried out
in an inpatient setting (87%) in the period between 1991
and 2002, but decreased (58%) in the period between
2003 and 2006. By 2007, most patients underwent surgi-
cal intervention as an outpatient (58%). Four surgical
interventions, two for each setting, were carried out in
2008. The distribution of inpatient and outpatient set-
tings was similar in the two subgroups across the total
analysis period; patients in subgroup 1 were treated in
an inpatient setting in 59% of cases and in an outpatient
setting in the other 41%.
Resource use
Laser vaporisation/excision after diagnostic biopsy for
h i s t o l o g yw e r et h em o s tc o m m o n surgical interventions
Table 1 Age, surgical interventions and visits to gynaecologists for diagnostic purposes
Subgroup I Subgroup II
Total
analysis
period
Main
analysis
period
Total
analysis
period
Main
analysis
period
N 52 52 n 42 42
Age at first SI (years) mean ± SD [range] 49.2 ± 13.8 [22-81] Age at first SI (years) mean ± SD [range] 43.6 ± 10.3
[21-71]
46.8 ± 10.4
[21-77]
Number of SI/pat.1 Number of SI/pat.2 - 5 1 - 5
Mean SI/pat. ± SD 1 Mean SI/pat. ± SD 3.0 ± 1.19 1.74 ± 0.91
Setting of SI Setting of SI
Inpatient 30 inpatient 64 32
Outpatient 21 outpatient 42 31
n/a 1 n/a 20 10
Total 52 Total 126 73
Number of VDP mean ± SD [range] 2.33 ± 1.64 [1-7] 1.54 ± 0.54 [1-3] Number of VDP mean ± SD [range] 6.26 ± 7.41
[1-41]
2.07 ± 1.24 [0-5]
Diagnoses Diagnoses in SI history
VIN2 7 VIN2 1 5
VIN3 40 VIN3 26 30
VIN2&VIN3 1 VIN2 - VIN3 11 3
VaIN2 2 VIN3 - VIN3&VaIN2 1 1
VIN3&VaIN3 2 VIN3 - VIN3&VaIN3 2 2
VIN3&VaIN2 1 1
Total 52 Total 42 42
Subgroup I: women who underwent one VIN 2/3 and/or VaIN 2/3 related surgery.
Subgroup II: women subjected to two or more VIN 2/3 and/or VaIN 2/3 related surgeries.
Total analysis period: period from first VIN 2/3 or VaIN 2/3 related to the last reported contact.
Main analysis period: period of one year before the reference intervention.
SI: surgical intervention(s).
VDP: visit(s) at dysplasia outpatient department or office based specialist for diagnostic purposes.
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resections or superficial partial vulvectomies were the
next most common (17%), often in combination with
laser vaporisation (8%). Diagnostic procedures regularly
accompanying an intervention were diagnostic biopsy,
smear, sonography and ECG, colposcopy, haematology
and chest X-ray. Patients who underwent more than
one surgical intervention had a mean of 1.74 interven-
tions during the main analysis period (inpatient setting
0.88; outpatient setting 0.86), and 3.0 interventions
during the total analysis period (inpatient setting 1.81;
outpatient setting 1.19; Table 2).
The mean number of outpatient visits for diagnostic
purposes presented in Table 1 are based on a total of 80
visits for diagnostic purposes in subgroup I (main analy-
sis period; 121 in the total analysis period) and 87 in
subgroup II (main analysis period; 263 in the total ana-
lysis period).
The mean duration spent on a ward for inpatient sur-
gery was 2.05 days for subgroup I and 4.9 days for
Table 2 Resource use and direct medical per-capita costs (incl. scenario analysis)
Resource use:
frequency
per patient
(patient
records)
Direct medical per-capita costs
Scenario analysis varying unit costs of 2007
mean [units] base case
(median unit
cost 2007)
best case
(lowest unit
cost 2007)
worst case
(highest unit
cost 2007)
Total analysis period
Total sample SI outpatient setting 0.76 €197.68 €90.54 €218.71
n=9 4 SI inpatient setting 1.13 €1,082.99 €1,077.83 €2,182.83
VDP 4.09 €366.42 €366.42 €487.24
Total €1,647.09 €1,534.79 €2,888.78
Subgroup I SI outpatient setting 0.41 €106.64 €48.84 €117.99
n=5 2 SI inpatient setting 0.59 €565.46 €562.76 €1,139.71
VDP 2.33 €208.74 €208.74 €277.57
Total €880.84 €820.35 €1,535.27
Subgroup II SI outpatient setting 1.19 €309.52 €141.76 €342.46
n=4 2 SI inpatient setting 1.81 €1,734.70 €1,726.43 €3,496.40
VDP 6.26 €560.83 €560.83 €745.75
Total €2,605.05 €2,429.03 €4,584.61
Main analysis period
Total sample SI outpatient setting 0.61 €158.66 €72.67 €175.55
n=9 4 SI inpatient setting 0.72 €690.05 €686.76 €1,390.83
VDP 1.77 €158.57 €158.57 €210.86
Total €1,007.28 €918.00 €1,777.24
Subgroup I SI outpatient setting 0.41 €106.64 €48.84 €117.99
n=5 2 SI inpatient setting 0.59 €565.46 €562.76 €1,139.71
VDP 1.54 €137.97 €137.97 €183.46
Total €810.07 €749.57 €1,441.16
Subgroup II SI outpatient setting 0.86 €223.69 €102.45 €247.49
n=4 2 SI inpatient setting 0.88 €843.39 €839.37 €1,699.90
VDP 2.07 €185.45 €185.45 €246.60
Total €1,252.53 €1,127.27 €2,193.99
Subgroup I: women who underwent one VIN 2/3 and/or VaIN 2/3 related surgery.
Subgroup II: women subjected to two or more VIN 2/3 and/or VaIN 2/3 related surgeries.
Total analysis period: period from first VIN 2/3 or VaIN 2/3 related to the last reported contact.
Main analysis period: period of one year before the reference intervention.
SI: surgical intervention(s).
VDP: patient visit(s) at dysplasia outpatient department or office based specialist for diagnostic purposes.
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total analysis period were 2.05 and 4.58 days,
respectively.
Direct medical and indirect costs
Patient records presented individually documented “his-
torical” costs (i.e. fees reimbursed by SHI in the respec-
tive year) per patient for surgical intervention and visits
for diagnostic purposes. “Historical” costs per surgical
intervention in the inpatient setting were variable over
time, amounting to a mean of €1,344.39 per intervention
(median €964.04; range: €484 to €13,764). Mean cost per
intervention in an outpatient setting was €200.28 and
the median was €239.62 (range €68.14 - €3,435.34).
Mean cost per visit for diagnostic purposes was €54.31
and the median was €40.80 (range €40.67 to €119.13).
Figure 2 demonstrates the trend curve for direct medi-
cal costs per case for each of the three categories over
the 1991-2008 period. Cost per inpatient surgery
remained relatively constant throughout the period. The
cost of outpatient surgery rose during those years, and
the cost of visits for diagnostic purposes increased from
2006 to 2007/2008.
Scenario analysis of direct medical cost used the aver-
age number of resource consumptions per patient (inpa-
tient surgery, outpatient surgery and visits for diagnostic
reason) as calculated from the numbers recorded in
patient records for all three scenarios. These numbers
were assigned the fees reimbursed by SHI to the study
site in 2007. Median fees for “base case” calculations
(lowest for “best case” and highest for “worst case”)
were:
￿€ 958.40 per inpatient surgery (lowest €953.83;
highest €1,931.71);
￿€ 260.10 per outpatient surgery (lowest €119.13;
highest €287.78);
￿€ 89.59 per visit for diagnostic reason (lowest
€89.59; highest €119.13).
Table 2 presents the resultant direct medical per-capita
cost. The base case scenario resulted in overall direct costs
of €1,007 (€1,253 in subgroup II and €810 in subgroup I)
during the main analysis period. Per-capita direct cost was
€1,647 (€2,605 and €881, respectively) for the whole per-
iod. Scenario analysis demonstrates that in a worst case
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Figure 2 Trend curve for mean direct medical cost per case. Zij = (Xij - μ)/s {i = 1, 2, 3; j = 1, 2, ..., 6} Xij: mean cost per case of category i in
time period j VDP: visit(s) at dysplasia outpatient department or office based specialist for diagnostic purposes.
Hampl et al. BMC Infectious Diseases 2011, 11:73
http://www.biomedcentral.com/1471-2334/11/73
Page 6 of 9scenario (i.e. using the highest documented cost for surgi-
cal intervention/visit for diagnostic purposes) the cost bur-
den is approximately double that of the best case scenario
(i.e. using the lowest documented costs). Costs for sub-
group II were three times higher than subgroup I across
the total analysis period and 1.5 times higher during the
main period. Historical direct medical costs taken from
patient records fit into the ranges given by the scenario
analysis based on 2007 unit costs. Indirect costs (Table 3)
ranged from approximately €650 in subgroup I during the
main analysis period to approximately €2,450 in subgroup
II for the total analysis period.
Estimated indirect costs were lower than direct costs
in the base case of scenario analysis; with the exception
of subgroup II in the total analysis period, where indir-
ect costs marginally exceeded direct costs.
Discussion
This study has presented initial data concerning the eco-
n o m i cb u r d e no fV I N2 / 3a n dV a I N2 / 3s u r g e r ya n d
related diagnostic procedures in Germany. The study
site is one of the top dysplasia centres.
Cost burden associated with VIN 2/3 and VaIN 2/3
surgery and related diagnostic procedures is part of the
Table 3 Total per-capita costs
Direct medical plus indirect per-capita costs
Direct medical
costs
Productivity
loss
Indirect costs Total costs
AB C = B * € 90 D = A + C
base case mean [days] Human capital
approach
base case
Total analysis period
Total sample SI outpatient setting €197.68 4.18 €376.13 €573.81
n=9 4 SI inpatient setting €1,082.99 9.98 €897.94 €1,980.93
VDP €366.42 2.04 €183.83 €550.25
Total €1,647.09 16.20 €1,457.90 €3,104.99
Subgroup I SI outpatient setting €106.64 2.26 €203.82 €310.46
n=5 2 SI inpatient setting €565.46 4.15 €373.24 €938.70
VDP €208.74 1.16 €104.71 €313.45
Total €880.84 7.58 €681.77 €1,562.61
Subgroup II SI outpatient setting €309.52 6.54 €588.40 €897.92
n=4 2 SI inpatient setting €1,734.70 17.35 €1,561.72 €3,296.42
VDP €560.83 3.13 €281.79 €842.62
Total €2,605.05 27.02 €2,431.90 €5,036.95
Main analysis period
Total sample SI outpatient setting €158.66 3.34 €300.25 €458.91
n=9 4 SI inpatient setting €690.05 6.10 €548.71 €1,238.76
VDP €158.57 0.88 €79.47 €238.04
Total €1,007.28 10.32 €928.43 €1,935.71
Subgroup I SI outpatient setting €106.64 2.26 €203.82 €310.46
n=5 2 SI inpatient setting €565.46 4.15 €373.24 €938.70
VDP €137.97 0.77 €69.23 €207.20
Total €810.07 7.18 €646.29 €1,456.36
Subgroup II SI outpatient setting €223.69 4.70 €423.35 €647.04
n=4 2 SI inpatient setting €843.39 8.65 €778.67 €1,622.06
VDP €185.45 1.04 €93.21 €278.66
Total €1,252.53 14.39 €1,295.23 €2,547.76
Subgroup I: women subjected to one VIN 2/3 and/or VaIN 2/3 related surgery.
Subgroup II: women who underwent two or more VIN 2/3 and/or VaIN 2/3 related surgeries.
Total analysis period: period from first VIN 2/3 or VaIN 2/3 related to the last reported contact.
Main analysis period: period of one year before the reference intervention.
SI: surgical intervention(s).
VDP: patient visit(s) at dysplasia outpatient department or office based specialist for diagnostic purposes.
Hampl et al. BMC Infectious Diseases 2011, 11:73
http://www.biomedcentral.com/1471-2334/11/73
Page 7 of 9overall burden due to HPV infections. Irrespective of
whether VIN and VaIN are rare diseases, these results
demonstrate that these costs should not be neglected in
general consideration of costs for HPV-related diseases.
In the inpatient setting, “historical” costs per surgical
intervention were variable over time. This variability is
most likely to be due to changes in the German reim-
bursement system for inpatient care, with SHI reimbur-
sement based on a per diem payment until 2004 and on
DRGs thereafter. Another explanation could be the
improvement in medical treatment options over time;
w eo b s e r v e das h i f tf r o ma ni n p a t i e n tt oa no u t p a t i e n t
setting, potentially resulting in the treatment of only
severe cases in hospital.
Patients who underwent one surgical intervention gen-
erated approximately €1,560 in “total” costs, with patients
undergoing more than one intervention (subgroup II)
generating approximately €5,030. As expected, subgroup
II had the highest per-capita resource consumption and
costs because there were more surgical interventions, and
the high unit cost of inpatient surgery added to direct
costs. Available data indicated that subgroup II contained
more seriously affected patients than subgroup I. Patients
were younger at the date of first surgery than patients
who underwent one intervention, and with respect to
inpatient surgery, the average length of stay in hospital
was twice as long as those in subgroup I. This indicates
that women subjected to two or more surgical interven-
tions require more complex treatment.
In 2008, Petry et al. published the results of a survey
carried out in Germany that collected data concerning
the cost of screening and treatment for cervical dyskar-
yosis. The study revealed total per-capita costs of €1,055
in the PAP III group (mean direct cost: €613; mean
indirect cost: €442) and of €3,174 in PAP IV group
(mean direct cost: €1,881; mean indirect cost: €1,293)
[15]. In 2008, the same authors presented annual costs
associated with genital warts in Germany, disclosing
direct medical costs ranging from €315 (men, new
cases) to €1,563 (women, resistant cases), and indirect
costs due to sick leave ranging from €0 (men and
women, new cases) to €232 (women, resistant cases)
[16]. Cost burden studies in other countries including
France and the United States [17-22] have used different
approaches, making the results incomparable. For exam-
ple, the average cost of CIN per episode of care was
$1,709 (CIN 1 = $1,026; CIN 2 = $1,300; and CIN 3 =
$3,235) in the United States [23].
There are limitations with this study as documents
f r o mas i n g l es i t ew e r eu s e da n dt h ed a t ac a n n o tb e
seen as representative for Germany. Furthermore, owing
to the low incidence of VIN 2/3 and VaIN 2/3 and the
restriction to one study site, only 94 patients were
included in the analysis. This is likely to have affected
the validity of the results and should be kept in mind
when interpreting and using these results for any further
analyses. This is why we refrained from extrapolating
them to the German population. However, the data give
a basic idea of the dimensions of the burden in Ger-
many where no cost data existed until now.
The costs presented are an excerpt of the total direct
medical and indirect costs. Not all outpatient visits per-
formed for diagnostic purposes are documented in patient
records at the study site, and documentation of surgical
interventions is not 100% complete. In addition, the study
was unable to include the cost of screening for VIN and
VaIN that did not lead to surgery. Further, the economic
burden associated with vaginal and vulvar cancer was not
included. Given that vulvar and vaginal cancers are rare
diseases compared to intraepithelial neoplasia [5] and that
we were limited to one study site, we expected during the
planning of the study such analyses would not have led to
valid results. Therefore, it was decided to not evaluate
these costs at the beginning of the study. Hence, the costs
presented here are likely to be underestimated, particularly
for the total analysis period.
Indirect costs could only be estimated. Patient records
did not contain information concerning sick leave days.
The numbers used for calculation were based on expert
opinion and should be viewed as data from experience.
The human capital approach, a relatively simple method
to quantify the monetary value of productivity losses
with its pros and cons, has been discussed extensively in
the literature [24-26]. A per diem productivity loss of
€90, cited in the 3rd edition of Hanover Consensus13, is
an approximation based on 2006. A precise 2007 figure
would have been marginally higher.
Conclusions
The economic burden on German statutory health
insurance funds and society induced by surgical inter-
ventions and related diagnostic procedures for grade 2/3
vulvar and vaginal neoplasia should not be underesti-
mated. The cost burden is part of the overall burden
attributable to HPV infections. Discussion of HPV infec-
tions should not focus solely on cervical cancer and pre-
cancers. Other HPV-induced tissue lesions and cancers
should be taken into account.
List of abbreviations
CIN: cervical intraepithelial neoplasia; DRG: Diagnosis Related Groups; HPV:
human papillomavirus; PAP: Papanicolaou; SHI: statutory health insurances;
SI: surgical intervention(s); US: United States; VaIN: vaginal intraepithelial
neoplasia; VDP: visit(s) at dysplasia outpatient department or office based
specialist for diagnostic purposes; VIN: vulvar intraepithelial neoplasia.
Acknowledgements
We are grateful to Julia Schiffner-Rohe, Sanofi Pasteur MSD GmbH, for her
helpful comments.
Hampl et al. BMC Infectious Diseases 2011, 11:73
http://www.biomedcentral.com/1471-2334/11/73
Page 8 of 9The project was supported by an unrestricted educational grant of Sanofi
Pasteur MSD GmbH, Leimen, Germany.
Author details
1Universitätsfrauenklinik Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany.
2Im Sand 4, 56412 Niedererbach, Germany.
3Institut für Experimentelle
Psychologie, Heinrich-Heine-Universtität, Universitätsstr. 1, 40225 Düsseldorf,
Germany.
4Sanofi Pasteur MSD GmbH, Paul-Ehrlich-Straße 1, 69181 Leimen,
Germany.
Authors’ contributions
MH designed the study, provided advice on medical topics and participated
in the writing of the manuscript. EH designed the study reviewed the results
and wrote the manuscript. OSH participated in designing the study and
collected the data. PK performed the statistical analysis. SS reviewed the
results of the study, participated in the writing of the manuscript and was
responsible for study coordination. All authors read and approved the final
manuscript.
Competing interests
MH declares that she has received an honorarium from Sanofi Pasteur MSD
and GlaxoSmithKline for speaking at several scientific meetings and for
acting as a scientific consultant. EH declares that he has received an
honorarium from Sanofi Pasteur MSD for acting as a scientific consultant. SS
is employed by Sanofi Pasteur MSD, who funded the study. OSH and PK
declare that they have no competing interests.
Received: 23 June 2010 Accepted: 22 March 2011
Published: 22 March 2011
References
1. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS,
Markowitz LE: Prevalence of HPV Infection Among Females in the United
States. JAMA 2007, 297:813-819.
2. Hu D, Goldie SJ: The Economic Burden of Noncervical Human
Papillomavirus Disease in the United States. Am J Obstet Gynecol 2008,
198:500.e1-500.e7.
3. Insinga RP, Dasbach EJ, Allen SE, Carides GW, Myers ER: Reductions in
Human Papillomavirus-Disease Resource Use and Costs with
Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18)
Recombinant Vaccination: The FUTURE Study Economic Evaluation. Value
Health 2008, 11:1022-1032.
4. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA: Trends in the
incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006,
107:1018-1022.
5. Anders S, Riethdorf L, Loening TH: Neoplasien und Praeneoplasien des
unteren Genitaltraktes. Gynäkologe 2001, 34:590-598.
6. Hampl M, Sarajuuri H, Wentzensen N, Bender HG, Kueppers V: Effect of
human papillomavirus vaccines on vulvar, vaginal, and anal
intraepithelial lesions and vulvar cancer. Obstet Gynecol 2006,
108:1361-1368.
7. Joura EA, Lösch A, Haider-Angeler MG, Breitenecker G, Leodolter S: Trends
in vulvar neoplasia. Increasing incidence of vulvar intraepithelial
neoplasia and squamous cell carcinoma of the vulva in young women. J
Reprod Med 2000, 45:613-615.
8. Jones RW, Rowan DM, Stewart AW: Vulvar intraepithelial neoplasia:
aspects of the natural history and outcome in 405 women. Obstet
Gynecol 2005, 106:1319-1326.
9. Hillemanns P, Wang X, Staehle S, Michels W, Dannecker C: Evaluation of
different treatment modalities for vulvar intraepithelial neoplasia (VIN):
CO(2) laser vaporization, photodynamic therapy, excision and
vulvectomy. Gynecol Oncol 2006, 100:271-275.
10. Hampl M, Wentzensen N, Vinokurova S, von Knebel-Doeberitz M,
Poremba C, Bender HG, Kueppers V: Comprehensive analysis of 130
multicentric intraepithelial female lower genital tract lesions by HPV
typing and p16 expression profile. J Cancer Res Clin Oncol 2007,
133:235-245.
11. van Seters M, van Beurden M, de Craen AJ: Is the assumed natural history
of vulvar intraepithelial neoplasia III based on enough evidence? A
systematic review of 3322 published patients. Gynecol Oncol 2005,
97:645-651.
12. Hording U, Junge J, Poulsen H, Lindvall F: Vulvar Intraepeitheal Neoplasia
III: A Viral Disease of Undetermined Progressive Potentential. Gynecol
Oncol 1995, 56:276-279.
13. Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R,
Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S,
Wasem J, Weber C, the Hanover Consensus Group: German
Recommendations on Health Economic Evaluation: Third and Updated
Version of the Hanover Consensus. Value Health 2008, 11:539-544.
14. GPS - Gute Praxis Sekundärdatenanalyse: Revision nach grundlegender
Überarbeitung. [http://www.dgepi.de/pdf/infoboard/stellungnahme/gps-
version2-final.pdf].
15. Petry KU, Breugelmans JG, Bénard S, Lamure E, Littlewood KJ, Hillemanns P:
Cost of screening and treatment of cervical dyskaryosis in Germany. Eur
J Gynaecol Oncol 2008, 29:245-249.
16. Hillemanns P, Breugelmans JG, Gieseking F, Bénard S, Lamure E,
Littlewood KJ, Petry KU: Estimation of the incidence of genital warts and
the cost of illness in Germany: A cross-sectional study. BMC Infectious
Diseases 2008, 8:76.
17. Rémy V, Mathevet P, Vainchtock A: Vulvar and vaginal cancers and
dysplasia in France–An analysis of the hospital medical information
system (PMSI) database. Eur J Obstet Gynecol 2009, 147:210-221.
18. Insinga RP, Dasbach EJ, Elbasha EH: Assessing the annual economic
burden of preventing and treating anogenital human papillomavirus-
related disease in the US–analytic framework and review of the
literature. PharmacoEcon 2005, 23:1107-1122.
19. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang SH: The health and
productivity cost burden of the “top 10” physical and mental health
conditions affecting six large US employers in 1999. J Occup Environ Med
2003, 45:5-14.
20. Insinga RP, Dasbach EJ, Myers ER: The health and economic burden of
genital warts in a set of private health plans in the United States. Clin
Infect Dis 2003, 36:1397-1403.
21. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL: The estimated direct
medical cost of sexually transmitted diseases among American youth,
2000. Perspect Sex Reprod Health 2004, 36:11-19.
22. Alam M, Stiller M: Direct medical costs for surgical and medical
treatment of condylomata acuminata. Arch Dermatol 2001, 137:337-341.
23. Insinga RP, Glass AG, Rush BB: The health care costs of cervical human
papillomavirus-related disease. Am J Obstet Gynecol 2004, 191:114-120.
24. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L: The friction
cost method for measuring indirect costs of disease. J Health Econ 1995,
14:171-189.
25. Johannesson M, Karlsson G: The friction cost method: A comment. J
Health Econ 1997, 16:249-255.
26. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L: Reply to
Johanneson’s and Karlsson’s comment. J Health Econ 1997, 16:257-259.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2334/11/73/prepub
doi:10.1186/1471-2334-11-73
Cite this article as: Hampl et al.: Economic burden of vulvar and vaginal
intraepithelial neoplasia: retrospective cost study at a German dysplasia
centre. BMC Infectious Diseases 2011 11:73.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hampl et al. BMC Infectious Diseases 2011, 11:73
http://www.biomedcentral.com/1471-2334/11/73
Page 9 of 9